Senhwa Biosciences’ Pidnarulex joins forces with global PD-1 leaders to advance next-gen immunotherapy
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Cagrilintide represents a novel approach to obesity management
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
Goyal reaffirmed the government’s commitment to facilitating market access, reducing trade barriers, and ensuring that Indian exporters remain globally competitive
Subscribe To Our Newsletter & Stay Updated